World Congress and Exhibition on
Pharmaceutics and Drug Delivery

Hiroshi Maeda is a world renowned expert in macromolecular therapeutics. He created the world first polymeric-conjugate drug, SMANCS, approved for treatment of hepatoma in Japan. Consequently, he discovered the concept of EPR effect of macromolecular-drugs, ubiquitous mechanism for solid tumor selective targeting of polymeric drugs. He received MS, University of California, Devis, Fulbright student, Ph.D., M.D., Tohoku University. He published more than 450 papers in reputed journals. He was awarded Lifetime-Achievement-Award at Royal-Pharmaceutical-Society, Princess-Takamatsu-Award in Cancer Research, Tomizo-Yoshida-Award, highest award of Japan-Cancer-Assoc., and also selected as most cited influential scientist in pharmacology by Thomson Reuters 2014, and H-index of 89.

Cancer chemotherapy, macromolecular therapeutics (polymer drugs), molecular pathology in cancer and infectious diseases, drug targeting, bacterial infection/ mechanism of pathogenesis of proteases/kallikrein/kinin, role of free radicals/ nitric oxide in infectious diseases and cancer, mutation, cancer prevention

Hiroshi Maeda is a world renowned expert in macromolecular therapeutics. He created the world first polymeric-conjugate drug, SMANCS, approved for treatment of hepatoma in Japan. Consequently, he discovered the concept of EPR effect of macromolecular-drugs, ubiquitous mechanism for solid tumor selective targeting of polymeric drugs. He received MS, University of California, Devis, Fulbright student, Ph.D., M.D., Tohoku University. He published more than 450 papers in reputed journals. He was awarded Lifetime-Achievement-Award at Royal-Pharmaceutical-Society, Princess-Takamatsu-Award in Cancer Research, Tomizo-Yoshida-Award, highest award of Japan-Cancer-Assoc., and also selected as most cited influential scientist in pharmacology by Thomson Reuters 2014, and H-index of 89.

Cancer chemotherapy, macromolecular therapeutics (polymer drugs), molecular pathology in cancer and infectious diseases, drug targeting, bacterial infection/ mechanism of pathogenesis of proteases/kallikrein/kinin, role of free radicals/ nitric oxide in infectious diseases and cancer, mutation, cancer prevention

Bruno Sarmento graduated in Pharmaceutical Sciences at the University of Porto (UP) in 2002 and completed a PhD in Pharmaceutical Nanotechnology at UP in 2007, in collaboration with Queens University (CA), University of Copenhagen (DK) and University of Santiago de Compostela (ES). From 2007 to 2012 he held a Post-Doc position at UP, in collaboration with the University of Copenhagen, investigating insulin intestinal absorption mechanisms using in vitro models. In 2008 he was appointed Assistant Professor at IUCS. He is currently visiting professor of the Post-Graduate School, UniOeste (BR). In 2012 he became Associated Researcher at INEB, where established an independent team. He was appointed as Assistant Researched at i3S (Institute for Investigation and Innovation in Health)/INEB in 2016. So far, he has supervised/co-supervised 8 Post-Docs, 29 PhD students (9 completed) and 23 MSc students (19 completed), and 6 researcher assistants. He also co-founded Inovapotek in 2008, and is member of its advisory board.

His current research is focused on the development of functionalized nanomedicines and their application in the pharmaceutical and biomedical fields. In particular, nanoformulations of biopharmaceutical drugs with interest in diabetes, cancer and infectious diseases. He has also specialized in mucosal tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation.

Dr. Kesavan Karthikeyan is a well-versed nanotechnologist, with expertise in developing nanoparticulate systems for delivering drugs to eye for the treatment of ocular diseases like glaucoma, uveitis, bacterial keratitis and allergic conjunctivitis. He obtained Ph.D from Indian Institute of Technology, Banaras Hindu University (IIT-BHU), Varanasi, and then he joined as Assistant Professor in SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur, C.G. in the year 2012. Currently, his group working on the development of the mucoadhesive nanoparticulate drug delivery systems for ocular drug delivery, which would offer the advantages of decreased dose and dosage regimen, sustained release, improved patient compliance, and enhanced safety profile. He has published more than 20 papers in reputed peer reviewed international journals. He has presented several papers in various national and international conferences. He extensively review manuscripts for many leading journals including Expert Opin Drug Deliv, Drug Dev Ind Pharm, Int J Pharm, Drug Deliv, Curr eye Res.

mucoadhesive nanoparticulate drug delivery systems for ocular drug delivery